Nyvepria (pegfilgrastim)

pCPA File Number: 21350

Negotiation Status:

Concluded with an LOI

Indication(s):

Febrile neutropenia in non-myeloid malignancies

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2021-01-13

Negotiation Process Concluded:

2021-04-05